Pankit Vachhani, MD, O'Neal Comprehensive Cancer Center

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice. 

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

What to look forward to in the polycythemia vera space, including new clinical trials.

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera. 

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.